| Literature DB >> 29951615 |
M Sandini1,2, E Pinotti1,2, I Persico1,3, D Picone1,3, G Bellelli1,3, L Gianotti1,2.
Abstract
BACKGROUND: Frailty is associated with poor prognosis, but the multitude of definitions and scales of assessment makes the impact on outcomes difficult to assess. The aim of this study was to quantify the effect of frailty on postoperative morbidity and mortality, and long-term mortality after major abdominal surgery, and to evaluate the performance of different frailty metrics.Entities:
Year: 2017 PMID: 29951615 PMCID: PMC5989941 DOI: 10.1002/bjs5.22
Source DB: PubMed Journal: BJS Open ISSN: 2474-9842
Figure 1PRISMA flow chart showing selection of articles for review
Characteristics of studies included in the systematic review and meta‐analysis
| Reference | Country | No. of patients |
Age |
Frail |
Type of | No. of items | Domains |
Morbidity | Mortality definition |
|---|---|---|---|---|---|---|---|---|---|
| Amrock | USA | 76 106 | 74·4 | n.r. | Lower GI | 5 | RDA; CO; NS; CF; A | NSQIP | 30 days |
| Amrock | USA | 76 106 | 74·4 | n.r. | Lower GI | 3 | CO; NS; A | NSQIP | 30 days |
| Buettner | USA | 1326 | 65 | n.r. | Mixed GI | 12 | RDA; CO (10); CA | CDC III–IV | 1 year |
| Buettner | USA | 1326 | 65 | 30·0 | Mixed GI | 1 | S | CDC III–IV | 1 year |
| Choi | Korea | 281 | 74·8 | 26·3 | Mixed abdominal | 9 | S; RDA (2); CO; NS (2); CF (2); CA | NSQIP | n.r. |
| Cohan | USA | 2493 | n.r. | 21·3 | Lower GI | 6 | RDA; CO (4); NS | NSQIP | n.r. |
| Courtney‐Brooks | USA | 37 | 73 | 16 | Gynaecological | 5 | PF; NS; DE; GS; W | NSQIP | n.r. |
| Dale | USA | 76 | 67·3 | n.r. | Upper GI | 4 | NS; DE; GS; W | CDC III–IV | n.r. |
| Erekson | USA | 22 214 | n.r. | 0·54 | Gynaecological | 1 | NS | Overall | n.r. |
| George | USA | 66 105 | n.r. | 15·5 | Gynaecological | 11 | RDA; CO (9); CF | CDC IV | 30 days |
| Hodari | USA | 2095 | n.r. | n.r. | Upper GI | 11 | RDA; CO (10) | n.r. | 30 days |
| Jones | UK | 100 | 68·6 | 15·0 | Lower GI | 1 | S | n.r. | n.r. |
| Kenig | Poland | 75 | 75 | 8 | Mixed GI | 8 | RDA (2); M; CO; NS; CF; DE; W | CDC III–IV | n.r. |
| Kim | Korea | 275 | 75·4 | 35·6 | Mixed abdominal | 9 | S; RDA (2); CO; NS (2); CF (2); CA | NSQIP | 1 year |
| Kristjansson | Norway | 178 | 76·6 | 42·7 | Lower GI | 7 | RDA (2); M; CO; NS; CF; DE | CDC III–IV | n.r. |
| Kuroki | USA | 122 | 65·9 | 50·0 | Gynaecological | 1 | S | n.r. | n.r. |
| Lascano | USA | 18 384 | 57·7 | n.r. | Urological | 15 | RDA; CO (10); NS; CF (2); CA | CDC IV | 30 days |
| Levy | USA | 23 104 | 61·9 | 54·8 | Urological | 15 | RDA; CO (10); NS; CF (2); CA | CDC IV | 30 days |
| Makary | USA | 594 | 72·8 | 10·4 | Mixed GI | 5 | RDA; NS; DE; GS; W | NSQIP | n.r. |
| Mogal | USA | 9986 | 64·1 | 6·4 | Upper GI | 11 | RDA; CO (10); | CDC III–IV | 30 days |
| Neuman | USA | 12 979 | 84·4 | 4·3 | Lower GI | 5 | CO; NS; W; F; O | n.r. | 90 days |
| Neuman | USA | 12 979 | 84·4 | 4·3 | Lower GI | 5 | CO; NS; W; F; O | n.r. | 1 year |
| Obeid | USA | 58 448 | n.r. | 12·8 | Lower GI | 11 | RDA; CO (10) | CDC IV | 30 days |
| Ommundsen | Norway | 178 | 80 | 42·7 | Lower GI | 6 | RDA; M; CO; NS; CF; DE | n.r. | 1 year |
| Pearl | USA | 4329 | n.r. | 67·2 | Urological | 11 | RDA; CO (10) | n.r. | n.r. |
| Reisinger | The Netherlands | 159 | n.r. | 25·8 | Lower GI | 7 | RDA; PF; M; NS; CF; VH; DE | Sepsis | 30 days |
| Revenig | USA | 214 | 62 | 16 | Mixed abdominal | 5 | PF; NS; DE; GS; W | Overall | n.r. |
| Revenig | USA | 80 | 60·0 | 23·4 | Mixed abdominal | 5 | PF; NS; DE; GS; W | CDC II–III–IV | n.r. |
| Revenig | USA | 351 | 63 | 27·3 | Mixed abdominal | 5 | RDA; NS; DE; GS; W | n.r. | 30 days |
| Robinson | USA | 72 | 74 | 33 | Lower GI | 8 | RDA; CO; NS; CF; W; A; F; O | VASQIP | n.r. |
| Saxton and Velanovich | USA | 226 | 61 | n.r. | Mixed GI | 70 | CSHA | Overall | 30 days |
| Saxton and Velanovich | USA | 226 | 61 | n.r. | Mixed GI | 70 | CSHA | CDC II–III–IV | n.r. |
| Sur | USA | 100 | 65·6 | 31·0 | Upper GI | 1 | DE | NSQIP | n.r. |
| Suskind | USA | 95 108 | n.r. | 21·5 | Urological | 11 | RDA; CO (10) | NSQIP | n.r. |
| Tan | Japan | 83 | 81·2 | 28 | Lower GI | 5 | RDA; NS; DE; GS; W | CDC II–III–IV | n.r. |
| Tegels | The Netherlands | 127 | 69·8 | 23·6 | Upper GI | 7 | RDA; PF; M; NS; CF; VH; DE | CDC III–IV | In hospital |
| Tegels | The Netherlands | 127 | 69·8 | n.r. | Upper GI | 7 | RDA; PF; M; NS; CF; VH; DE | CDC III–IV | 6 months |
| Uppal | USA | 6551 | n.r. | n.r. | Gynaecological | 11 | RDA; CO (10) | CDC III–IV | n.r. |
| Velanovich | USA | 727 041 | n.r. | n.r. | Mixed abdominal | 11 | RDA; CO (10) | Overall | 30 days |
| Velanovich | USA | 23 569 | n.r. | n.r. | Gynaecological | 11 | RDA; CO (10) | Overall | 30 days |
| Wagner | USA | 518 | 72 | 25·1 | Upper GI | 1 | S | n.r. | 1 year |
Values are mean or median.
Values in parentheses are number of items used to create the domain.
Prospective studies; the others were retrospective.
Uppal and colleagues52 considered two different scores for the same metric system, on the same population; morbidity outcomes are reported separately for the two scores. n.r., Not reported; GI, gastrointestinal; RDA, reduced daily activities; CO, co‐morbidity; NS, nutritional status; CF, cognitive function; A, anaemia; NSQIP, National Surgical Quality Improvement Program; CA, cancer; CDC, Clavien–Dindo classification; S, sarcopenia; PF, physical fitness; DE, depression/exhaustion; GS, grip strength; W, walking test; M, medication; F, falls; O, others; VH, visual and hearing deficit; VASQIP, Veterans Affairs Surgical Quality Improvement Program; CSHA, Canadian Study of Health and Aging 70 Item Frailty Score.
Figure 2Forest plot of the effect of frailty on major postoperative morbidity. Odds ratios are shown with 95 per cent confidence intervals
Figure 3Forest plots of the effect of frailty on a short‐term and b long‐term mortality. Odds ratios and hazard ratios are shown with 95 per cent confidence intervals
Analysis of studies reporting the effect size for each item of the score in predicting major postoperative morbidity
| Reference |
Reduced | Sarcopenia | Co‐morbidities |
Nutritional |
Cognitive |
Depression/ |
Walking | No. of patients |
|---|---|---|---|---|---|---|---|---|
| Odds ratio | ||||||||
| Amrock | 2·08 (1·89, 2·32) | – | – | 1·34 (1·28, 1·40) | 1·21 (1·10, 1·43) | – | – | 76 106 |
| Amrock | – | – | 1·09 (1·00, 1·18) | 1·45 (1·43, 1·58) | – | – | – | 76 106 |
| Buettner | – | 2·28 (1·72, 3·01) | – | – | – | – | – | 1326 |
| Choi | 3·66 (0·94, 14·20) | 4·57 (1·98, 10·50) | 1·27 (0·55, 2·89) | 3·25 (1·42, 7·46) | 3·01 (1·31, 6·90) | – | – | 281 |
| Dale | – | – | – | 0·81 (0·29, 2·26) | – | 4·04 (1·40, 11·80) | 1·02 (0·50, 2·06) | 76 |
| Jones | – | 4·81 (1·32, 17·60) | – | – | – | – | – | 100 |
| Erekson | – | – | – | 2·49 (1·48, 4·17) | – | – | – | 22 214 |
| Kenig | 1·70 (0·50, 5·80) | – | 1·20 (0·40, 3·50) | 1·10 (0·40, 2·90) | 1·70 (0·50, 5·80) | 1·10 (0·20, 2·40) | 3·60 (1·10, 13·40) | 75 |
| Kuroki | – | 0·74 (0·35, 1·58) | – | – | – | – | – | 122 |
| Revenig | 1·11 (0·59, 2·10) | – | – | 1·90 (1·22, 2·96) | – | 1·49 (0·94, 2·36) | 1·63 (0·69, 3·86) | 351 |
| Sur | – | 4·72 (1·26, 17·7) | – | – | – | 3·70 (1·21, 1·71) | – | 100 |
| Overall | 1·85 (1·29, 2·66) | 2·52 (1·32, 4·80) | 1·09 (1·00, 1·18) | 1·45 (1·31, 1·62) | 1·65 (0·89, 3·07) | 2·13 (1·12, 4·06) | 1·56 (0·82, 2·97) | |
|
| 0·001 | 0·005 | 0·041 | < 0·001 | 0·112 | 0·022 | 0·174 | |
|
| 31·8 | 70·7 | 0 | 65·6 | 58·5 | 45·6 | 34·5 | |
|
| 0·220 | 0·008 | 0·923 | 0·008 | 0·090 | 0·028 | 0·217 | |
| No. of patients | 76 813 | 1929 | 76 462 | 175 209 | 76 462 | 602 | 502 |
Values in parentheses are 95 per cent confidence intervals.